Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Core Insights - Marker Therapeutics, Inc. announced a collaboration with Cellipont Bioservices for the cGMP manufacturing of MT-601, a leading MAR-T cell therapy aimed at treating hematological malignancies and solid tumors [1][3] Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [6] - The company has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [6] Clinical Development - MT-601 is currently in the Phase 1 APOLLO study targeting patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or are ineligible for it, with a reported 78% objective response rate and 44.4% complete response rate among participants [2] - The collaboration with Cellipont aims to support the scale-up and production of MT-601, facilitating clinical supply and potential pivotal trials [3][4] Manufacturing Partnership - Cellipont Bioservices will provide technology transfer and cGMP manufacturing services to Marker Therapeutics, leveraging its state-of-the-art facility designed for high-quality cell therapy production [3][4] - The partnership is expected to enhance the clinical development and future commercial production capabilities for MT-601 [4][5] Strategic Importance - The collaboration is viewed as a critical step for Marker Therapeutics in preparing for potential pivotal trials, particularly for patients with diffuse large B-cell lymphoma [4] - Both companies emphasize a shared commitment to quality and innovation in advancing next-generation immunotherapies [5]